Tuesday, 10 Jun 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • House
  • White
  • VIDEO
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Colossal
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > Teva’s Layoffs Signal Deeper Fault Lines In The Pharma Business Model
Health and Wellness

Teva’s Layoffs Signal Deeper Fault Lines In The Pharma Business Model

Last updated: June 2, 2025 9:06 am
Share
Teva’s Layoffs Signal Deeper Fault Lines In The Pharma Business Model
SHARE

The recent announcement that Teva Pharmaceuticals will lay off roughly 2,400 employees–approximately 8% of its global workforce–is a significant development in a sector already under strain. This move aims to save $700 million by 2027 as Teva attempts to rebalance its role as both a generics manufacturer and a player in branded pharmaceuticals.

It reveals a deep challenge facing generics manufacturers in the U.S. and globally: the current market structure does not reward the cost-saving potential of generic or biosimilar drugs. Instead, it privileges the profit margins of expensive branded medications.

Teva’s layoffs aren’t just a corporate adjustment, they’re a symptom of a drug market that’s fundamentally out of balance. We need to rethink how we reward innovation, control costs and structure distribution. Lasting change will require curbing PBM influence and redesigning incentives to reward value and competition.

Teva’s layoffs highlight a stark reality: generic drugs no longer offer a reliable path to growth in the U.S. market. PBMs, regulations and pricing incentives have warped the system to the point where generics and biosimilars–once seen as the key to sustainable drug costs–are no longer viable business models.

In a country where generics account for nearly 90% of prescriptions but only a small fraction of total drug spending, manufacturers face razor-thin margins and limited commercial upside. Unlike branded drugs, generics do not benefit from formulary placement incentives, advertising or preferential reimbursement.

This issue is compounded by global pricing distortions. In Europe, generic drugs are often priced higher than in the U.S., allowing manufacturers to capture reasonable returns abroad. But in America’s free-market healthcare system, companies ironically find themselves unable to compete due to PBM-driven pricing strategies that reward high list prices and rebate structures over net-cost affordability.

See also  Samsung Galaxy Watch 8 Leak Confirms Classic Model Return

At the heart of the dysfunction is the pharmacy benefit manager. PBMs were originally intended to negotiate lower prices on behalf of employers and health plans. But as I discuss in a previous column, over time their profit model has shifted toward maximizing rebate revenue, most of which is derived from expensive branded medications.

PBMs claim to support cost savings and patient affordability. Yet in practice, they often exclude generics and biosimilars from formularies if these alternatives don’t come with a lucrative rebate. As a result, lower-cost competitors are blocked from market access, despite having met rigorous FDA approval standards. The rebate-driven model warps clinical decision-making, inflates costs and ultimately harms patients and taxpayers.

The branded pharmaceutical sector deserves credit for high-risk innovation. Developing a new drug takes upwards of $2 billion in investment and years of research, with no guarantee of success. It’s reasonable for manufacturers to recoup those costs, and then some, on successful assets.

But that justification becomes murky when the financial system continues to reward branded products long after they’ve lost exclusivity, purely because of channel economics. When a biosimilar or generic alternative becomes available, the transition should be smooth, guided by comparative value and patient benefit.

Instead, branded products often retain dominance through financial agreements with PBMs, payers and providers, rather than clinical necessity. There is a place for both branded and generic drugs in a functioning market, but the rules must be rational and transparent.

Teva’s layoffs, like the recent downsizing at Biogen and Bristol Myers Squibb, are not isolated incidents. They are predictable consequences of an industry that has become dependent on distorted incentives and short-term financial engineering. The U.S. drug pricing system rewards the wrong actors, discourages healthy competition and drives up costs without corresponding improvements in value or outcomes.

See also  Guess the Top Model in This Poolside Pic

The solution is not to vilify pharmaceutical manufacturers. Rather, we need to create a competitive, value-based market–one that rewards innovation, encourages adoption of cost-saving alternatives and removes the financial bottlenecks imposed by intermediaries.

If we’re serious about controlling drug costs, ensuring patient access and maintaining global leadership in pharmaceutical innovation, we must take a hard look at the economic levers shaping the industry. That starts with realigning the roles of manufacturers, PBMs and policymakers.

Teva’s restructuring should be a wake-up call, not just for generics manufacturers, but for the entire healthcare ecosystem. The system is not broken beyond repair, but it is misaligned in ways that threaten sustainability, affordability and public trust. Rebalancing these forces is a national security and public health necessity.

TAGGED:BusinessdeeperfaultLayoffsLinesModelPharmasignalTevas
Share This Article
Twitter Email Copy Link Print
Previous Article Brad Pitt ‘Risks Relationship For Jennifer Aniston Brad Pitt ‘Risks Relationship For Jennifer Aniston
Next Article Elon Musk says XChat is rolling out to all, but questions remain about its alleged security Elon Musk says XChat is rolling out to all, but questions remain about its alleged security
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Cops shoot, kill armed man while responding to domestic incident, CPD says

Chicago police officers were involved in a fatal shooting early Friday morning at the Albany…

January 3, 2025

Great Divide Brewing closing Denver taprooms

A Legacy Denver Brewery to Close Taprooms Following Acquisition A well-known Denver brewery, Great Divide…

May 27, 2025

‘Gutfeld!’ Comedian Tyler Fischer Claims ‘Woke’ Fox News Banned Him

Tyler Fischer, a comedian who has made appearances on Fox News‘ “Gutfeld!” primetime show, recently…

April 18, 2025

David Moreno’s Anthropomorphic Foundations Support Cascading Villages — Colossal

David Moreno, a talented artist based in Barcelona, creates stunning sculptures using thin rods of…

September 19, 2024

Dr. Mehmet Oz tapped to lead Medicare, Medicaid: Trump Transition

President-elect Trump has made a significant announcement, naming the renowned surgeon and television personality Dr.…

November 19, 2024

You Might Also Like

The Real Medicaid Crisis Isn’t Cuts—It’s The Model Itself
Health and Wellness

The Real Medicaid Crisis Isn’t Cuts—It’s The Model Itself

June 10, 2025
Organ transplant groups use loophole to boost ratings
Health and Wellness

Organ transplant groups use loophole to boost ratings

June 10, 2025
Orgasms aren’t the sole key to women’s sexual satisfaction, study finds
Health and Wellness

Orgasms aren’t the sole key to women’s sexual satisfaction, study finds

June 10, 2025
AI Agents Are Coming To Healthcare
Health and Wellness

AI Agents Are Coming To Healthcare

June 10, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?